RPRX long view for year 2025
Stock is consolidating above R4 camarilla levels in weekly time frame.
It has come out of a big consolidation. It is consistently paying dividends and is trading at a very attractive PE multiple.
It seems buying this is like buying biopharmaceuticals portfolio. Not betting on a single biopharmaceutical stock but a company which is buying royalties and is funder of innovations. This should be more than enough diversification in single holding.
It is having very relevant portfolio for current geopolitical situation.
I think, 42$ would be fair value from technical analysis and intrinsic value should be around 80$.
YoY EPS need to cross 5.08 levels before the 80 levels get realized rapidly as there shall be QoQ earnings growth acceleration. Till then conservative view of 40$ to 42$.
It has come out of a big consolidation. It is consistently paying dividends and is trading at a very attractive PE multiple.
It seems buying this is like buying biopharmaceuticals portfolio. Not betting on a single biopharmaceutical stock but a company which is buying royalties and is funder of innovations. This should be more than enough diversification in single holding.
It is having very relevant portfolio for current geopolitical situation.
I think, 42$ would be fair value from technical analysis and intrinsic value should be around 80$.
YoY EPS need to cross 5.08 levels before the 80 levels get realized rapidly as there shall be QoQ earnings growth acceleration. Till then conservative view of 40$ to 42$.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.